Layoffs at Gossamer Bio
- Layoff events
- 2
- verified and sourced
- Roles reported
- At least 73
- events with no figure are not in this number
- Announced between
- May 2023 to Mar 2026
- Reported by
- Gossamer Bio, U.S. Securities and Exchange Commission, and Fierce Biotech
This page records what we could verify and source. It is not a complete record of every job cut at Gossamer Bio: a layoff nobody published and nobody sent us is a layoff that is not on this page.
| Company | What happened | Roles reported | Share of staff | Where | Announced | Sources |
|---|---|---|---|---|---|---|
| Gossamer Bio |
Pipeline setback
Gossamer Bio implemented a workforce reduction after the Phase 3 PROSERA study failed to meet its primary endpoint, while shifting resources toward remaining programs and strategic priorities. |
73 | Not known | Company-wide | ||
| Gossamer Bio |
Pipeline setback
Gossamer Bio announced a 25% workforce reduction and stopped work on other assets to focus resources on a Phase 3 pulmonary-arterial-hypertension program. |
Not known | 25% | United States |
1 source for Gossamer Bio |
Where this comes from
Every cut listed for Gossamer Bio was entered by a person who checked it against a filing or a named report. Nothing is scraped and nothing publishes itself. What is not here is what we have not verified, not what did not happen.
Spotted something wrong or missing about Gossamer Bio? Tell us on our Discord and we will check it.